This is the first study to investigate the clinical significance of plasma sIL-6R and sgp130 levels and the ratios of binary IL-6:sIL-6R and ternary IL-6:sIL-6R:sgp130 complexes in ICI-treated NSCLC patients. This evidence concerns the gene IL6R and non-small cell lung carcinoma.